Zoetis (ZTS) Q2 2026: Flat Revenue Hid a $132M Pet Drop
Zoetis is valued as a companion-animal growth company. In the second quarter of 2026 that engine ran backwards: U.S. companion animal revenue fell to $1,044 million from $1,176 million, a drop of $132 million, or 11.2%, according to the company's Form 10-Q for the quarter ended June 30, 2026. Total revenue barely moved — $2,468 million against $2,474 million — because livestock and international sales added back almost exactly what the U.S. pet business lost. Reported earnings per share still rose.
Two things qualify that flat headline. The $2,474 million comparative is a recast figure — Zoetis originally reported $2,460 million for the quarter — so it will not tie to last year's filing (section 4-1). And on the same day, Zoetis cut its full-year revenue guidance from $9.680–9.960 billion to $9.120–9.320 billion, turning expected organic operational growth of 2% to 5% into a decline of 2% to 4% (section 5). The quarter looks flat. The year no longer does.
1. The Balance Sheet Shrank on Purpose — $974M of Cash Went Out the Door
Zoetis spent the first half dismantling its own balance sheet to support the share count. Total assets fell 2.7% and equity fell 7.8%, and neither was caused by a weak business.
1-1. Cash Left the Building; Receivables and Inventory Did Not
The line to watch below is the first one. Cash was the only working asset that fell.
| Item | Dec 31, 2025 ($M) | Jun 30, 2026 ($M) | Change % |
|---|---|---|---|
| Cash and cash equivalents | 2,450 | 1,476 | −39.8 |
| Short-term investments | — | 200 | n/a |
| Accounts receivable | 1,409 | 1,571 | +11.5 |
| Inventories | 2,464 | 2,574 | +4.5 |
| Property, plant and equipment, net | 3,693 | 3,756 | +1.7 |
| Identifiable intangible assets, net | 998 | 918 | −8.0 |
| Goodwill | 2,774 | 2,771 | −0.1 |
| Total assets | 15,490 | 15,077 | −2.7 |
Cash fell by $974 million. Adding back the new $200 million of short-term investments, liquid resources still fell 31.6%.
Two working-capital lines deserve attention. Receivables rose 11.5% in six months while first-half revenue rose 1.2%. Inventory rose 4.5% even as the largest product franchise shrank — work-in-process alone went from $991 million to $1,069 million. A company building stock into a declining U.S. pet market is making a bet that the decline is temporary.
Operating lease right-of-use assets were $275 million against $289 million, and lease liabilities $190 million. Neither figure moves the analysis.
1-2. A Convertible Struck at $148, Shares Bought Back at $90
Long-term debt was essentially unchanged at $9,048 million versus $9,042 million. The structure, however, tells a story the totals hide.
In December 2025 Zoetis issued $2.0 billion of 0.250% convertible senior notes due 2029, at a conversion price of approximately $148.20 per share. Net proceeds were $1,970 million. Of that, $187 million funded capped calls, $248 million bought 2.1 million shares immediately, and $1,535 million bought a further 12.3 million shares, repurchases the filing says were completed as of March 31, 2026. Most of that block settled in December 2025 rather than this year: the first-half 2026 equity rollforward records only 11.0 million shares retired in total. Effectively the entire issue was converted into retired stock.
The execution prices since then are worth reading twice. Zoetis bought back 11.0 million shares for $1,170 million in the first half (equity rollforward basis), an average of $106.4 per share. The second quarter alone accounted for 6.2 million shares at $558 million — $90.0 per share. That implies roughly $127.5 per share in the first quarter ($612 million for 4.8 million shares). The stock the company hedged at $148.20 in December was being bought at $90 by June.
Total principal is $9,150 million at a weighted-average coupon of 3.23%. Excluding the near-zero-coupon convertible, the rest of the stack averages 4.06%. Maturities through 2029 total $4,100 million, or 44.8% of principal, with the $2.0 billion convertible the single largest tower. The fair value of that debt was $8,456 million against $9,150 million of principal — 92.4% of par, down from $8,842 million at year-end.
Leverage remains well inside the covenant. Net debt of roughly $7,372 million against annualized first-half EBITDA near $4.2 billion implies about 1.75 times, against a 3.50:1 maximum. Nothing was drawn on the $1.25 billion revolver.
1-3. Zoetis Has Bought Back 81 Cents of Every Dollar It Ever Retained
Retained earnings reached $14,653 million, up $855 million — first-half net income of $1,292 million less $436 million of declared dividends and $1 million of share-based compensation adjustments. Against that sits treasury stock of $11,845 million, now equal to 80.8% of cumulative retained earnings. Paid-in capital is only $1,131 million.
The result is a very thin equity base: $3,148 million supporting $15,077 million of assets, an equity ratio of 20.9%, down from 22.0%. Debt to equity moved from 2.65 to 2.87 times. Accumulated other comprehensive loss improved slightly, from −$804 million to −$796 million.
2. Strip Out Severance and Operating Profit Never Moved
The reported profit decline was manufactured by a restructuring charge. Underlying operating profit was flat.
2-1. The $132M That Left, and the $130M That Replaced It
Zoetis does not present an operating income subtotal, so the figures below are computed from disclosed line items — revenue less cost of sales, SG&A, R&D, amortization and restructuring.
| Item (Q2) | 2024 ($M) | 2025 ($M) | 2026 ($M) | 2Y CAGR |
|---|---|---|---|---|
| Revenue | 2,361 | 2,474 | 2,468 | +2.2% |
| Operating profit (computed) | — | 967 | 922 | — |
| Operating margin (%) | — | 39.1 | 37.4 | — |
| Operating profit ex-restructuring | — | 997 | 999 | — |
| Net income | 624 | 726 | 691 | +5.2% |
| Net margin (%) | 26.4 | 29.3 | 28.0 | — |
The 2024 column is taken from that year's filing and has not been recast for the accounting change described in section 4-1. Treat it as trend direction, not a like-for-like comparison.
Restructuring and acquisition-related costs jumped to $77 million from $30 million, of which $74 million was employee termination costs against $5 million a year earlier. Remove that line from both years and operating profit was $999 million versus $997 million — flat, at a margin of 40.5% against 40.3%. The entire reported deterioration is the cost program.
Below the line, interest expense rose to $61 million from $53 million and the tax rate eased to 20.2% from 20.4%. Pretax income fell 5.0% and net income fell 4.8%.
Operating leverage is not measurable this quarter because revenue barely moved. Over the half it is: revenue rose 1.2% while operating profit excluding restructuring rose 0.7%, a ratio of about 0.6 — costs grew marginally faster than sales.
The revenue mix is where the quarter actually happened.
| Q2 revenue | 2025 ($M) | 2026 ($M) | Change ($M) | Change % |
|---|---|---|---|---|
| U.S. companion animal | 1,176 | 1,044 | −132 | −11.2 |
| U.S. livestock | 180 | 222 | +42 | +23.3 |
| International companion animal | 614 | 664 | +50 | +8.1 |
| International livestock | 471 | 509 | +38 | +8.1 |
| Contract manufacturing & human health | 33 | 29 | −4 | −12.1 |
| Total | 2,474 | 2,468 | −6 | −0.2 |
Cattle added the most revenue of any species, $390 million against $323 million, up 20.7% — though U.S. livestock grew faster in percentage terms, at 23.3%. Dogs and cats fell to $1,634 million from $1,719 million. The United States dropped to 51.3% of revenue from 54.8%.
The 10-Q gives no product-level explanation for the U.S. decline. The company's Q2 2026 results announcement does: lower clinic visits and pet-owner price sensitivity cut demand, while competition intensified in key categories. The dermatology franchise and Simparica Trio faced heightened competitive pressure, generic entrants hit Cerenia and Convenia, and Librela sales fell. None of those three causes is a timing effect, which is the reason the full-year outlook moved with them (section 5).
2-2. The Cost Program Is Real, and Most of the Bill Is Unpaid
Management protected research and cut selling. R&D rose 4.2% to $173 million, or 7.0% of revenue, while SG&A fell 3.6% to $592 million, or 24.0% of revenue from 24.8%. Cost of sales rose 1.4% on slightly lower revenue, compressing gross margin to 72.8% from 73.2%.
The severance is largely accrued rather than paid. The restructuring accrual went from $25 million at year-end to $95 million, on a $95 million provision and only $25 million of utilization. Roughly $93 million sits in accrued expenses and will consume cash in later periods.
Note that under US GAAP all R&D is expensed as incurred. Zoetis margins are therefore not directly comparable with IFRS-reporting peers that capitalize development costs.
3. Two Dollars Returned for Every Dollar of Free Cash Flow
Shareholder distributions ran at roughly twice free cash flow, and the gap was paid out of the cash balance.
| Item (H1) | 2025 ($M) | 2026 ($M) | Change |
|---|---|---|---|
| Operating cash flow | 1,120 | 1,056 | −5.7% |
| Investing cash flow | (415) | (387) | — |
| Financing cash flow | (1,241) | (1,653) | — |
| Capital expenditure | (324) | (227) | −29.9% |
| Free cash flow | 796 | 829 | +4.1% |
| Ending cash | 1,632 | 1,476 | −9.6% |
Free cash flow improved to $829 million, but only because capital expenditure was cut by 30%. Capex fell to 4.8% of revenue from 6.9%. Operating cash flow itself declined 5.7%, held back by a $172 million receivables build and a $137 million inventory build. Those cash-flow figures run ahead of the balance-sheet moves of $162 million and $110 million because the cash flow statement strips out currency translation.
Earnings quality is below one and has been for both periods. Operating cash flow covered 82% of net income, against 84% a year earlier. Cash conversion is not collapsing, but it is not improving either.
Against $829 million of free cash flow, Zoetis paid $1,190 million for buybacks (cash flow statement basis; the equity rollforward records $1,170 million, the difference reflecting a prior-period excise tax accrual settled in cash this period) and $447 million in dividends — $1,637 million, or 197% of free cash flow, up from 154%. Buybacks alone rose 52.4%.
One detail explains the dividend arithmetic. Dividends declared per share rose 6.0%, to $1.060 from $1.000 for the half. Total cash dividends paid were identical at $447 million in both years. The 6% raise cost nothing because there were 5.66% fewer shares to pay it on. The buyback funded the dividend increase.
4. What the Notes Change About the Headline
4-1. Last Year's Comparison Is Not the One You Remember
Effective January 1, 2026, Zoetis eliminated the one-month reporting lag previously applied to non-U.S. subsidiaries and moved their year-end to December 31. This is a change in accounting principle, applied retrospectively. The 2025 comparatives in this filing have been recast: second-quarter revenue went from the $2,460 million originally reported to $2,474 million, an increase of $14 million.
That direction matters for how the quarter reads. Against the recast $2,474 million — the only like-for-like comparison, since both periods then exclude the lag — revenue slipped 0.2%. Against the originally published $2,460 million it rose 0.3%, but that calculation puts a new-basis 2026 figure next to an old-basis 2025 one and is not a valid comparison. Either way the move is $6 million to $8 million on $2.5 billion, which is noise; the substance of the quarter is the mix underneath it, not the sign of the total.
The company states it will also recast the third-quarter 2025 and the full-year 2025 and 2024 statements when they next appear as comparatives. Any comparison against previously published 2025 numbers will not tie.
4-2. The Buyback Pace Nearly Tripled
Share retirement has been a steady feature at Zoetis. Its acceleration has not. Weighted-average basic shares in the second quarter fell 1.0% in 2022, 1.7% in 2023, 1.4% in 2024 and 2.3% in 2025 — then 6.2% in 2026, to 417.6 million from 445.1 million. In share terms, second-quarter purchases rose from 2.1 million shares in 2025 to 6.2 million — nearly three times as many.
This is what carried EPS. Basic EPS was $1.65 against $1.63. On the prior year's sh
